Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL, JUN 03-07, 2016
-
2016 (v1)Journal articleUploaded on: December 3, 2022
-
October 18, 2017 (v1)Conference paper
Many researches have been conducted in the last decades on the determination of the minimal clinically important difference(MCID) for health-related quality of life (HRQOL) scores. Several methods have been proposed, generally classified in distribution oranchor-based methods. A joint use of both distribution and anchorbased approaches, using...
Uploaded on: December 3, 2022 -
July 2017 (v1)Journal article
International audience
Uploaded on: February 28, 2023 -
August 2016 (v1)Journal article
Glioblastoma is the most common malignant brain tumor in adults. Baseline health‐related quality of life (HRQoL) is a major subject of concern for these patients. We aimed to assess the independent prognostic value of HRQoL in unresectable glioblastoma (UGB) patients for death risk stratification. One hundred and thirty‐four patients with UGB...
Uploaded on: December 4, 2022 -
December 2023 (v1)Journal article
Purpose Radiotherapy is, with surgery, one of the main therapeutic treatment strategies for meningiomas. No prospective study has defined a consensus for the delineation of target volumes for meningioma radiotherapy. Therefore, target volume definition is mainly based on information from retrospective studies that include heterogeneous patient...
Uploaded on: July 8, 2023 -
2022 (v1)Journal article
BACKGROUND: Incidence and characteristics of pseudoprogression in isocitrate dehydrogenase-mutant high-grade gliomas (IDHmt HGG) remain to be specifically described. METHODS: We analyzed pseudoprogression characteristics and explored the possibility of pseudoprogression misdiagnosis in IDHmt HGG patients, treated with radiotherapy (with or...
Uploaded on: December 3, 2022 -
August 2012 (v1)Journal article
Purpose of this study was to determine the effect of waiting time for radiotherapy on overall survival of patients with glioblastoma treated in the EORTC-NCIC trial at 18 centers in France. A total of 400 adult patients with glioblastoma who were treated between January 1, 2006 and December 31, 2006 were included. There were 282 patients with...
Uploaded on: December 2, 2022